<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: investment", fill: "#c89"},
{source: "1: investment", target: "1: common stock involves", fill: "#c89"},
{source: "1: investment", target: "2: carefully", fill: "#843f5b"},
{source: "2: carefully", target: "2: risks described", fill: "#843f5b"},
{source: "2: risks described", target: "2: common stock", fill: "#843f5b"},
{source: "2: carefully", target: "4: Additional ", fill: "#e08d3c"},
{source: "4: Additional ", target: "4: presently known", fill: "#e08d3c"},
{source: "4: presently known", target: "4: immaterial may also adversely affect", fill: "#e08d3c"},
{source: "4: Additional ", target: "11: may never generate", fill: "#ae0c00"},
{source: "11: may never generate", target: "11: become profitable even", fill: "#ae0c00"},
{source: "11: become profitable even", target: "11: commercialize", fill: "#ae0c00"},
{source: "11: may never generate", target: "13: accumulated deficit as", fill: "#af4035"},
{source: "13: accumulated deficit as", target: "13: December ", fill: "#af4035"},
{source: "13: accumulated deficit as", target: "37: Potential ", fill: "#228b22"},
{source: "37: Potential ", target: "37: products may fail", fill: "#228b22"},
{source: "37: products may fail", target: "37: necessary regulatory approvals", fill: "#228b22"},
{source: "37: necessary regulatory approvals", target: "37: difficult", fill: "#228b22"},
{source: "37: difficult", target: "37: manufacture on", fill: "#228b22"},
{source: "37: manufacture on", target: "37: market acceptance", fill: "#228b22"},
{source: "37: market acceptance", target: "37: third parties", fill: "#228b22"},
{source: "37: Potential ", target: "60: named us as", fill: "#465945"},
{source: "60: named us as", target: "60: counterclaim defendant", fill: "#465945"},
{source: "60: counterclaim defendant", target: "60: misappropriation", fill: "#465945"},
{source: "60: misappropriation", target: "60: proprietary rights", fill: "#465945"},
{source: "60: proprietary rights", target: "60: seeks monetary damages", fill: "#465945"},
{source: "60: seeks monetary damages", target: "60: injunctive relief", fill: "#465945"},
{source: "60: injunctive relief", target: "60: intellectual property", fill: "#465945"},
{source: "60: named us as", target: "61: counterclaim", fill: "#7c0a02"},
{source: "61: counterclaim", target: "61: liability", fill: "#7c0a02"},
{source: "61: counterclaim", target: "65: Default Under Our Debentures", fill: "#72a0c1"},
{source: "65: Default Under Our Debentures", target: "66: Convertible Debentures ", fill: "#a67b5b"},
{source: "66: Convertible Debentures ", target: "66: Debentures ", fill: "#a67b5b"},
{source: "66: Debentures ", target: "66: without limitation failure", fill: "#a67b5b"},
{source: "66: without limitation failure", target: "66: principal interest", fill: "#a67b5b"},
{source: "66: principal interest", target: "66: agreement", fill: "#a67b5b"},
{source: "66: agreement", target: "66: agreements", fill: "#a67b5b"},
{source: "66: agreements", target: "66: facility", fill: "#a67b5b"},
{source: "66: facility", target: "66: obligations", fill: "#a67b5b"},
{source: "66: obligations", target: "66: ineligibility", fill: "#a67b5b"},
{source: "66: ineligibility", target: "66: effectiveness", fill: "#a67b5b"},
{source: "66: effectiveness", target: "66: registration statement registering", fill: "#a67b5b"},
{source: "66: registration statement registering", target: "66: inability", fill: "#a67b5b"},
{source: "66: inability", target: "66: selling stockholders", fill: "#a67b5b"},
{source: "66: selling stockholders", target: "66: sell shares thereunder", fill: "#a67b5b"},
{source: "66: sell shares thereunder", target: "66: certain blackout periods", fill: "#a67b5b"},
{source: "66: certain blackout periods", target: "66: of the February ", fill: "#a67b5b"},
{source: "66: Convertible Debentures ", target: "83: adequately protect", fill: "#bc987e"},
{source: "83: adequately protect", target: "83: intellectual", fill: "#bc987e"},
{source: "83: intellectual", target: "83: property competitors may", fill: "#bc987e"},
{source: "83: property competitors may", target: "83: technologies", fill: "#bc987e"},
{source: "83: adequately protect", target: "START_HERE", fill: "#bc987e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Finance">Finance</a></td>
      <td>Finance is the study and discipline of money, currency and capital assets. It is related with, but not synonymous with economics, the study of production, distribution, and consumption of money, assets, goods and services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_Mathematics">Additional Mathematics</a></td>
      <td>Additional Mathematics is a qualification in mathematics, commonly taken by students in high-school (or GCSE exam takers in the United Kingdom). It is applied to a range of problems set out in a different format and wider content to the standard Mathematics at the same level.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_director_general_of_police">Additional director general of police</a></td>
      <td>Additional Director General of Police (ADGP) is an Indian Police Service rank. Though having the maximum possible 3-star police rank just like Director General of Police,  ADGP's are considered same to DGP's.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_member_system">Additional member system</a></td>
      <td>The additional member system (AMS) is a mixed electoral system under which most representatives are elected in single-member districts (SMDs), and the other "additional members" are elected to make the seat distribution in the chamber more proportional to the way votes are cast for party lists. It is distinct from parallel voting (also known as the supplementary member system) in that the "additional member" seats are awarded to parties taking into account seats won in SMDs (referred to as compensation or "top-up"), which is not done under parallel voting (a non-compensatory method).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Order_of_Australia">Order of Australia</a></td>
      <td>The Order of Australia is an honour that recognises Australian citizens and other persons for outstanding achievement and service. It was established on 14 February 1975 by Elizabeth II, Queen of Australia, on the advice of the Australian Government.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additionality">Additionality</a></td>
      <td>Additionality is the property of an activity being additional by adding something new to the context. It is a determination of whether an intervention has an effect when  compared to a baseline.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Latin_Extended_Additional">Latin Extended Additional</a></td>
      <td>Latin Extended Additional is a Unicode block.\nThe characters in this block are mostly precomposed combinations of Latin letters with one or more general diacritical marks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_Standards_on_Auditing">International Standards on Auditing</a></td>
      <td>International Standards on Auditing (ISA) are professional standards for the auditing of financial information. These standards are issued by the International Auditing and Assurance Standards Board (IAASB).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Liability">The Liability</a></td>
      <td>The Liability (also known as The Hitman's Apprentice) is a 2013 British black comedy crime-thriller film directed by Craig Viveiros and written by John Wrathall. The film stars Tim Roth, Talulah Riley, Jack O'Connell and Peter Mullan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability_partnership">Limited liability partnership</a></td>
      <td>A limited liability partnership (LLP) is a partnership in which some or all partners (depending on the jurisdiction) have limited liabilities. It therefore can exhibit elements of partnerships and corporations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vicarious_liability">Vicarious liability</a></td>
      <td>Vicarious liability is a form of a  strict, secondary liability that arises under the common law doctrine of agency, respondeat superior, the responsibility of the superior for the acts of their subordinate or, in a broader sense, the responsibility of any third party that had the "right, ability or duty to control" the activities of a violator. It can be distinguished from contributory liability, another form of secondary liability, which is rooted in the tort theory of enterprise liability because, unlike contributory infringement, knowledge is not an element of vicarious liability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Salomon_v_A_Salomon_&amp;_Co_Ltd">Salomon v A Salomon &amp; Co Ltd</a></td>
      <td>Salomon v A Salomon &amp; Co Ltd [1896] UKHL 1, [1897] AC 22 is a landmark UK company law case. The effect of the House of Lords' unanimous ruling was to uphold firmly the doctrine of corporate personality, as set out in the Companies Act 1862, so that creditors of an insolvent company could not sue the company's shareholders for payment of outstanding debts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Debenture_(sport)">Debenture (sport)</a></td>
      <td>In corporate finance, a debenture is a medium- to long-term debt instrument used by large companies to borrow money, at a fixed rate of interest. The legal term "debenture" originally referred to a document that either creates a debt or acknowledge it, but in some countries the term is now used interchangeably with bond, loan stock or note.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Law_Debenture">Law Debenture</a></td>
      <td>The Law Debenture Corporation plc is a leading British-based investment trust dedicated to a diversified range of investments. It also provides a range of fiduciary services including appointment of agents, directors and trustees for pension funds, trusts and companies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_capital">Financial capital</a></td>
      <td>Financial capital (also simply known as capital or equity in finance, accounting and economics) is any economic resource measured in terms of money used by entrepreneurs and businesses to buy what they need to make their products or to provide their services to the sector of the economy upon which their operation is based, e.g., retail, corporate, investment banking, etc. In other words, financial capital is internal retained earnings generated by the entity or funds provided by lenders (and investors) to businesses in order to purchase real capital equipment or services for producing new goods and/or services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gold_exchange-traded_product">Gold exchange-traded product</a></td>
      <td>Gold exchange-traded products are exchange-traded funds (ETFs), closed-end funds (CEFs) and exchange-traded notes (ETNs) that are used to own gold as an investment. Gold exchange-traded products are traded on the major stock exchanges including the SIX Swiss Exchange, the Bombay Stock Exchange, the London Stock Exchange, the Paris Bourse, and the New York Stock Exchange.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Championships,_Wimbledon">The Championships, Wimbledon</a></td>
      <td>The Championships, Wimbledon, commonly known simply as Wimbledon or The Championships, is the oldest tennis tournament in the world and is widely regarded as the most prestigious. It has been held at the All England Club in Wimbledon, London since 1877 and is played on outdoor grass courts, with retractable roofs over the two main courts since 2019.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Security_(finance)">Security (finance)</a></td>
      <td>A security is a tradable financial asset. The term commonly refers to any form of financial instrument, but its legal definition varies by jurisdiction.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_Kingfisher_Airlines">History of Kingfisher Airlines</a></td>
      <td>Kingfisher Airlines was established in 2003 and ceased operations when its license was cancelled on 20 October 2012. It is owned by the Bengaluru based United Breweries Group.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PRO PHARMACEUTICALS INC      Item 1A    Risk Factors          An <font color="blue">investment</font> in our <font color="blue"><font color="blue">common stock</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You should     <font color="blue">carefully</font> consider the <font color="blue">risks described</font> below and the other information     before deciding to invest in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are     not the <font color="blue">only ones facing</font> our company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">presently known</font>     to us or that we currently consider <font color="blue">immaterial may also adversely affect</font> our     business</td>
    </tr>
    <tr>
      <td>We have attempted to identify below the <font color="blue">major factors</font> that could     cause <font color="blue">differences between actual</font> and planned or expected results, but we     <font color="blue">cannot assure</font> you that we have identified all of those factors</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> happen, our business, financial     condition and operating results could be <font color="blue">materially <font color="blue">adversely affected</font></font></td>
    </tr>
    <tr>
      <td>In     this case, the <font color="blue">trading price</font> of our <font color="blue">common stock</font> could decline, and you     <font color="blue">could lose</font> all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Pro-Pharmaceuticals (<font color="blue">dollar amounts</font> in thousands)          We  Are  at  an  Early  Stage  of  <font color="blue"><font color="blue">Development </font> </font>with Limited Operating     History</td>
    </tr>
    <tr>
      <td>We have no     <font color="blue">therapeutic</font>  products  available for sale, and none are expected to be     <font color="blue">commercially available</font> for <font color="blue">several years</font>, if at all</td>
    </tr>
    <tr>
      <td>We <font color="blue">may never generate</font>     revenue or become profitable, even if we are able to <font color="blue">commercialize</font> any     products</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>We Have Incurred Net Losses to Date and Depend on <font color="blue">Outside Capital</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">accumulated deficit as</font> of <font color="blue">December </font>31, 2005 was dlra26cmam430</td>
    </tr>
    <tr>
      <td>We will need to     continue  to  conduct  <font color="blue">significant</font>  research, <font color="blue">development</font>, testing and     <font color="blue"><font color="blue">regulatory</font> compliance activities</font> that, <font color="blue">together with</font> projected general and     <font color="blue">administrative expenses</font>, we expect will result in substantial operating     losses for the next <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Accordingly, we will not be <font color="blue">generating</font>     sales or other revenue and <font color="blue">will remain dependent on outside sources</font> of     <font color="blue">financing during</font> that time</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">raise funds from outside</font>     sources for our <font color="blue">continuing <font color="blue">operations</font></font>, we may be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may raise such capital through public</font> or <font color="blue">private <font color="blue">equity financings</font></font>,     partnerships, debt financings, bank borrowings, or other sources</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>    <font color="blue">funding may</font> not be <font color="blue">available on</font> favorable terms or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font>     are  not  otherwise  available,  we  may need to <font color="blue">significant</font>ly curtail     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To  obtain  <font color="blue"><font color="blue">additional</font> funding</font>, we may need to <font color="blue">enter into</font>     <font color="blue">arrangements</font> that require us to <font color="blue">relinquish rights</font> to <font color="blue">certain <font color="blue">technologies</font></font>,     products and/or potential markets</td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue">additional</font> capital is     raised through the sale of equity, or securities convertible into equity,     our equity holders may experience dilution of their <font color="blue">proportionate</font> ownership     of the company</td>
    </tr>
    <tr>
      <td>Based on dlra4cmam466 of <font color="blue">available cash</font> and <font color="blue">cash equivalents as</font> of <font color="blue">December </font>31,     2005, and <font color="blue">approximately</font> dlra9dtta3 million of <font color="blue">net proceeds raised through issuance</font>     of <font color="blue">Convertible <font color="blue">Debentures </font></font>on <font color="blue">February </font>14, 2006 we believe that we have     <font color="blue">sufficient capital</font> to fund our <font color="blue">operations</font> through at least June 2007</td>
    </tr>
    <tr>
      <td><font color="blue">Our Product Candidates Will Be Based </font>on <font color="blue">Novel Unproven Technologies</font></td>
    </tr>
    <tr>
      <td>Our     product  <font color="blue"><font color="blue">candidates</font> will</font> be <font color="blue"><font color="blue">based on</font> novel unproven <font color="blue">technologies</font> using</font>     <font color="blue"><font color="blue">proprietary</font> carbohydrate compounds</font> in <font color="blue">combination with</font> FDA approved of drugs     <font color="blue">currently used</font> in the treatment of cancer and other diseases</td>
    </tr>
    <tr>
      <td><font color="blue">Carbohydrates     </font>are  <font color="blue">difficult</font>  to  synthesize,  and  we may not be able to synthesize     <font color="blue">carbohydrates</font> that would be <font color="blue">usable as delivery vehicles</font> for the anti-cancer     drugs we plan to work with</td>
    </tr>
    <tr>
      <td><font color="blue">Our Drug Candidates </font>are in <font color="blue">Clinical Trials and Results Are Uncertain</font></td>
    </tr>
    <tr>
      <td>We     have <font color="blue">one product candidate</font> in <font color="blue"><font color="blue">human clinical</font> trials</font></td>
    </tr>
    <tr>
      <td>Pre-clinical results in     <font color="blue">animal studies</font> are not <font color="blue">necessarily predictive</font> of outcomes in <font color="blue">human clinical</font>     trials</td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font>trials are expensive, time-consuming and may not be     successful</td>
    </tr>
    <tr>
      <td>They involve the testing of potential <font color="blue">therapeutic</font> agents, or     <font color="blue"><font color="blue">effective</font> treatments</font>, in humans, typically in <font color="blue">three phases</font>, to determine the     safety and efficacy of the <font color="blue"><font color="blue">product <font color="blue">candidates</font></font> <font color="blue">necessary</font></font> for an approved     drug</td>
    </tr>
    <tr>
      <td>Many products in <font color="blue"><font color="blue">human clinical</font> trials</font> fail to <font color="blue">demonstrate</font> the desired     safety  and  efficacy  <font color="blue">characteristics</font></td>
    </tr>
    <tr>
      <td>Even if our products progress     <font color="blue"><font color="blue">successfully</font> through initial human testing</font>, they may fail in <font color="blue">later stages</font> of     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We will be <font color="blue">dependent on others</font> to conduct our <font color="blue">clinical trials</font>,     including    clinical    research    <font color="blue"><font color="blue">organization</font>s</font>    and,   possibly,     government-sponsored agencies</td>
    </tr>
    <tr>
      <td>These <font color="blue">trials may</font> not start or be completed as     we forecast, or may be <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>Even if     our <font color="blue">product <font color="blue">candidates</font></font> are successful in <font color="blue">clinical trials</font>, they may not be     <font color="blue">successfully</font>  <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td><font color="blue">Potential  </font><font color="blue">products may fail</font> to receive     <font color="blue"><font color="blue">necessary</font> <font color="blue">regulatory</font> approvals</font>, be <font color="blue">difficult</font> to <font color="blue"><font color="blue">manufacture</font> on</font> a large     scale, be uneconomical to produce, fail to achieve <font color="blue">market acceptance</font>, or be     precluded from <font color="blue">commercialization</font> by <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We have limited experience in <font color="blue">manufacturing</font> or <font color="blue">procuring products</font>     in  commercial  quantities, conducting other later-stage phases of the     <font color="blue">regulatory</font>  approval  process,  selling  <font color="blue">pharmaceutical</font>  products,  or     negotiating, establishing and maintaining <font color="blue">strategic relationships</font></td>
    </tr>
    <tr>
      <td>Any     growth of our <font color="blue">company will</font> require us to expand our <font color="blue">management</font> and our     operational and <font color="blue">financial systems</font> and controls</td>
    </tr>
    <tr>
      <td>If we are unable to do so,     our business and <font color="blue">financial condition would</font> be <font color="blue">materially harmed</font></td>
    </tr>
    <tr>
      <td>If rapid     growth occurs, it may strain our operational, managerial and financial     resources</td>
    </tr>
    <tr>
      <td>We  Will  Depend  on  Third  Parties  to  <font color="blue">Manufacture  </font>and  Market Our     Products</td>
    </tr>
    <tr>
      <td>We do not have, and do not now intend to develop, <font color="blue">facilities</font>     for  the <font color="blue">manufacture</font> of any of our products for clinical or commercial     production</td>
    </tr>
    <tr>
      <td>Accordingly,  we  will need to develop <font color="blue">relationships with</font>     <font color="blue">manufacture</font>rs and <font color="blue">enter into</font> collaborative <font color="blue">arrangements</font> with licensees or     have others <font color="blue">manufacture</font> our <font color="blue">products on</font> a <font color="blue">contract basis</font></td>
    </tr>
    <tr>
      <td>We expect to     <font color="blue">depend on such collaborators</font> to supply us with products <font color="blue">manufacture</font>d in     <font color="blue">compliance with standards imposed by</font> the FDA and foreign <font color="blue">regulators</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>In addition, we have limited experience in marketing, sales or <font color="blue">distribution</font>,     and we do not intend to develop a sales and <font color="blue">marketing infrastructure</font> to     <font color="blue">commercialize</font>  our  <font color="blue">pharmaceutical</font>  products</td>
    </tr>
    <tr>
      <td>If we develop commercial     products, we will need to rely on licensees, collaborators, joint venture     partners or <font color="blue">independent distributors</font> to market and sell those products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> Dr</td>
    </tr>
    <tr>
      <td>David Platt, President and     Chief Executive Officer; Dr</td>
    </tr>
    <tr>
      <td>Anatole Klyosov, our <font color="blue">chief scientist</font>; and     Dr</td>
    </tr>
    <tr>
      <td>The loss of any of these persons, or failure to attract or retain other key     personnel, <font color="blue">could prevent</font> us from pursuing collaborations or developing our     products and <font color="blue">core <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>Platt filed a lawsuit in <font color="blue">Massachusetts in January </font>2004 against GlycoGenesys,     Inc</td>
    </tr>
    <tr>
      <td>In its answer GlycoGenesys     <font color="blue">named us as</font> a <font color="blue"><font color="blue">counterclaim</font> defendant</font> alleging tortious interference and     <font color="blue">misappropriation</font> of <font color="blue"><font color="blue">proprietary</font> rights</font>, and <font color="blue">seeks monetary damages</font> and     <font color="blue">injunctive relief</font> related to our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>In March 2004, we     answered the <font color="blue">counterclaim</font> and denied any <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Platt intend     to contest these <font color="blue">counterclaim</font>s vigorously</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">prevail there could</font>     be  a  material  adverse  <font color="blue">impact on</font> our <font color="blue">financial position</font>, results of     <font color="blue">operations</font> or <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>We Could Be Required to Make Substantial Cash Payments Upon an Event of     <font color="blue">Default Under Our Debentures</font></td>
    </tr>
    <tr>
      <td>Our 7prca <font color="blue">Convertible <font color="blue">Debentures </font></font>provide for     events of default including, without limitation, failure to timely make     payments of principal, interest or other <font color="blue">amounts due</font> thereunder, failure to     observe or perform any covenant or <font color="blue">agreement</font> set forth in the <font color="blue">Debentures </font>or     other material <font color="blue">agreement</font>s to which we are a party, default on another credit     <font color="blue">agreement</font>  or  <font color="blue">facility</font>  evidencing  of <font color="blue">obligations</font> in excess of dlra250,     <font color="blue">ineligibility</font> of our stock for listing on quotation on a trading market,     lapse of <font color="blue"><font color="blue">effective</font>ness</font> of the <font color="blue">registration statement <font color="blue">registering</font></font> the shares     subject to this prospectus or <font color="blue">inability</font> of <font color="blue">selling <font color="blue">stockholders</font></font> to offer and     <font color="blue">sell shares thereunder</font> in excess of certain “blackout” periods, and failure     to have the shares registered within 180 days after the <font color="blue">February </font>14, 2006     date of sale of the <font color="blue">Debentures </font>and warrants</td>
    </tr>
    <tr>
      <td>If an event of default occurs,     the <font color="blue">outstanding principal</font>, plus accrued and <font color="blue">unpaid interest</font> due thereon, and     all other <font color="blue">amounts due</font> under each <font color="blue">Debenture </font>may become, at the holder’s     election, <font color="blue">immediately</font> due and payable in cash in an amount that is not less     than the sum of (i) 130prca of the <font color="blue"><font color="blue">outstanding principal</font> plus accrued</font> and     <font color="blue">unpaid interest</font> and (ii) other <font color="blue">amounts due</font> to such holder</td>
    </tr>
    <tr>
      <td>We would not be     able to repay this amount without raising <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>Please see     “<font color="blue">Description  </font>of  Transaction”  below  for <font color="blue">additional</font> detail about the     <font color="blue">Debentures </font>and warrants</td>
    </tr>
    <tr>
      <td>For  as  long as at least dlra1 million of our 7prca Convertible     <font color="blue">Debentures </font><font color="blue">remains outstanding</font>, we cannot take <font color="blue">certain actions</font>, including,     among others, incurrence of <font color="blue">indebtedness beyond</font> a stated amount, <font color="blue">amendment</font>s     of our charter or governance documents, repurchase or other <font color="blue">acquisition</font> of     more  than  a  de  minimis number of the shares of our <font color="blue">common stock</font> or     securities exercisable, convertible or exchangeable for shares of our common     stock</td>
    </tr>
    <tr>
      <td>These  negative covenants may limit actions, such as a finance     <font color="blue">transaction</font> that requires an <font color="blue">amendment</font> of our <font color="blue">certificate</font> of <font color="blue">organization</font>,     that we believe are in the <font color="blue">best interests</font> of Pro-Pharmaceuticals but which     we cannot complete if the holders of the <font color="blue">Debentures </font>do not consent</td>
    </tr>
    <tr>
      <td>We     currently do not have <font color="blue">products approved</font> for sale <font color="blue">in the US </font>or any foreign     market</td>
    </tr>
    <tr>
      <td>We are required to obtain <font color="blue">approval from</font> the FDA in order to sell our     products <font color="blue">in the US </font>and from foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> in order to     sell our products in other countries</td>
    </tr>
    <tr>
      <td>The FDA’s review and <font color="blue">approval process</font>     is lengthy, expensive and uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Extensive </font>pre-clinical and clinical     data  and supporting information must be submitted to the FDA for each     <font color="blue">indication</font> for each product candidate in order to secure FDA approval</td>
    </tr>
    <tr>
      <td>The     FDA <font color="blue">could reject</font> an <font color="blue">application</font> or require us to conduct <font color="blue">additional</font> clinical     or  other  <font color="blue">studies as</font> part of the <font color="blue">regulatory</font> review process</td>
    </tr>
    <tr>
      <td>Delays in     obtaining or failure to obtain FDA <font color="blue">approvals would prevent</font> or delay the     <font color="blue">commercialization</font> of our products, which would prevent, defer                                           15     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>or  decrease our receipt of revenues</td>
    </tr>
    <tr>
      <td>If we receive initial <font color="blue">regulatory</font>     approval, our product <font color="blue"><font color="blue">candidates</font> will</font> be subject to extensive and rigorous     <font color="blue">ongoing domestic</font> and <font color="blue">foreign government regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>and protection of our <font color="blue"><font color="blue">intellectual</font> property</font> are     critical to our business</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">adequately protect</font> our <font color="blue">intellectual</font>     property, <font color="blue">competitors</font> may be able to practice our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our success     depends in part on our ability to obtain <font color="blue">patent protection</font> for our products     or  processes  in the <font color="blue">United States </font>and other countries, protect trade     secrets, and <font color="blue">prevent others from infringing on</font> our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Since patent <font color="blue">application</font>s in the <font color="blue">United States </font>are maintained in secrecy for     at  <font color="blue">least portions</font> of their pendency periods (published on US patent     issuance  or, if earlier, 18 months from earliest filing date for most     <font color="blue">application</font>s) and since other <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific     or patent literature often lags behind actual <font color="blue">discoveries</font>, we cannot be     certain that we are the first to make the <font color="blue">inventions</font> to be <font color="blue">covered by</font> our     patent  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>The  <font color="blue">patent position</font> of bio<font color="blue">pharmaceutical</font> firms     <font color="blue">generally</font>  is  <font color="blue">highly uncertain</font> and <font color="blue">involves complex legal</font> and factual     questions</td>
    </tr>
    <tr>
      <td><font color="blue">The US Patent and Trademark Office </font>has not established a     <font color="blue">consistent policy</font> regarding the breadth of claims that it will allow in     <font color="blue"><font color="blue">biotechnology</font> patents</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that all of our patent <font color="blue">application</font>s will issue as     patents or that the claims of any <font color="blue">issued patents will afford meaningful</font>     protection for our <font color="blue">technologies</font> or products</td>
    </tr>
    <tr>
      <td>In addition, patents issued to     us or our <font color="blue">licensors may</font> be challenged and subsequently narrowed, invalidated     or  <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> is widespread in the <font color="blue">biotechnology</font>     industry and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>might be <font color="blue">necessary</font> to     protect  our <font color="blue">patent position</font> or to determine the scope and validity of     third-party <font color="blue"><font color="blue">proprietary</font> rights</font>, and we may not have the required resources     to pursue such <font color="blue">litigation</font> or to protect our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>Although we require our scientific and <font color="blue">technical employees</font> and <font color="blue">consultants</font>     to <font color="blue">enter into</font> broad assignment of <font color="blue">inventions</font> <font color="blue">agreement</font>s, and all of our     employees, <font color="blue">consultants</font> and <font color="blue">corporate partners with access</font> to <font color="blue">proprietary</font>     information to <font color="blue">enter into</font> confidentiality <font color="blue">agreement</font>s, these <font color="blue">agreement</font>s may     not be honored</td>
    </tr>
    <tr>
      <td>We are a <font color="blue"><font color="blue">counterclaim</font> defendant</font> in a <font color="blue">lawsuit instituted by</font> Dr</td>
    </tr>
    <tr>
      <td>We  cannot  assure  that  products  <font color="blue">based on</font> our patents or     <font color="blue"><font color="blue">intellectual</font> property</font> that we <font color="blue">license from others will</font> not be <font color="blue">challenged by</font>     a <font color="blue">third party</font> claiming <font color="blue">infringement</font> of its <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>If we were     not able to <font color="blue">successfully</font> defend our patents or <font color="blue">licensed rights</font>, we may have     to pay substantial damages, possibly including <font color="blue">treble damages</font>, for past     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">biotechnology</font> and <font color="blue">pharmaceutical</font> industries are intensely     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face direct competition from</font> US and foreign companies     focusing on drug delivery <font color="blue">technologies</font>, which are rapidly evolving</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font>  include  major, multinational <font color="blue">pharmaceutical</font> and chemical     companies,  specialized <font color="blue">biotechnology</font> firms and <font color="blue">universities</font> and other     <font color="blue">research <font color="blue">institutions</font></font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have greater financial and     other resources, larger research and <font color="blue">development</font> staffs and more <font color="blue">effective</font>     marketing and <font color="blue">manufacturing</font> <font color="blue"><font color="blue">organization</font>s</font>, than we do</td>
    </tr>
    <tr>
      <td>In addition, academic     and <font color="blue">government <font color="blue">institutions</font></font> are <font color="blue">increasingly likely</font> to <font color="blue">enter into</font> exclusive     licensing <font color="blue">agreement</font>s with commercial enterprises, including our <font color="blue">competitors</font>,     to  market  commercial  products <font color="blue">based on</font> technology developed at such     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">competitors</font> may succeed in developing or licensing     <font color="blue">technologies</font> and products that are more <font color="blue">effective</font> or <font color="blue">less costly than ours</font>,     or  succeed in obtaining FDA or other <font color="blue">regulatory</font> approvals for product     <font color="blue">candidates</font> before we do</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our products <font color="blue">successfully</font>     will be <font color="blue">affected by</font> the <font color="blue">ongoing efforts</font> of <font color="blue">governmental</font> and third-party     payors to contain the cost of <font color="blue">health care</font></td>
    </tr>
    <tr>
      <td>These entities are <font color="blue">challenging</font>     prices of <font color="blue">health care</font> products and                                           16     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>services, denying or <font color="blue">limiting coverage</font> and <font color="blue">reimbursement amounts</font> for new     <font color="blue">therapeutic</font> products, and for FDA-approved products considered <font color="blue">experimental</font>     or <font color="blue">investigational</font>, or which are used for disease <font color="blue">indication</font>s without FDA     <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>Even if we succeed in bringing any products to the market, they may not be     considered  cost-<font color="blue">effective</font>  and third-party reimbursement might not be     available or sufficient</td>
    </tr>
    <tr>
      <td>If adequate third-party coverage is not available,     we  may  not be able to maintain <font color="blue">price levels sufficient</font> to realize an     <font color="blue">appropriate return on</font> our <font color="blue">investment</font> in research and product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In     addition,   <font color="blue">legislation</font>  and  <font color="blue">regulations</font>  <font color="blue">affecting</font>  the  pricing  of     <font color="blue">pharmaceutical</font>s may change in <font color="blue">ways adverse</font> to us before or after any of our     <font color="blue">proposed products</font> are approved for marketing</td>
    </tr>
    <tr>
      <td>In the     future, we may, in the <font color="blue">ordinary course</font> of business, be subject to claims by,     and <font color="blue">liability</font> to, persons alleging injury as a result of taking products we     have under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If we are successful in having <font color="blue">products approved</font> by     the FDA, the sale of such products would expose us to <font color="blue">additional</font> potential     product <font color="blue">liability</font> and other claims resulting from their use</td>
    </tr>
    <tr>
      <td>This <font color="blue">liability</font>     may result from claims made <font color="blue">directly by consumers</font> or by <font color="blue">pharmaceutical</font>     companies  or <font color="blue">others selling such products</font></td>
    </tr>
    <tr>
      <td>Although we currently have     <font color="blue">insurance coverage</font> for both product <font color="blue">liability</font> and professional <font color="blue">liability</font>, it     is  possible  that  we  will not be able to maintain <font color="blue">such insurance on</font>     acceptable terms</td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to maintain <font color="blue">insurance coverage</font> on acceptable     terms  <font color="blue">could prevent</font> or limit the <font color="blue">commercialization</font> of any products we     develop</td>
    </tr>
    <tr>
      <td>The  <font color="blue">market price</font> for securities of bio<font color="blue">pharmaceutical</font> and     <font color="blue">biotechnology</font> companies historically has <font color="blue">been highly volatile</font>, and the     market  from time-to-time has experienced <font color="blue">significant</font> price and volume     <font color="blue">fluctuations</font>  that  are unrelated to the operating performance of such     companies</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in the <font color="blue">trading price</font> or liquidity of our common     <font color="blue">stock may adversely affect</font> our ability to <font color="blue">raise capital through future</font>     <font color="blue">equity financings</font></td>
    </tr>
    <tr>
      <td>We listed     our <font color="blue">common stock</font> on the <font color="blue">American Stock Exchange in September </font>2003, prior to     which our <font color="blue">stock traded on</font> the <font color="blue">OTC Bulletin Board</font></td>
    </tr>
    <tr>
      <td>Based <font color="blue">on varying trading</font>     volume to date, our <font color="blue">stock could</font> be considered “<font color="blue">thinly traded</font></td>
    </tr>
    <tr>
      <td>” In 2003 and     2004,  on  behalf  of <font color="blue">existing <font color="blue">stockholders</font></font>, we registered for re-sale     <font color="blue">approximately</font> 14dtta65 million shares of our <font color="blue">common stock</font>, and <font color="blue">approximately</font>     3dtta61 million  shares  of  stock  <font color="blue">issuable upon exercise</font> of <font color="blue">immediately</font>     exercisable  warrants</td>
    </tr>
    <tr>
      <td>On behalf of the holders of our 7prca Convertible     <font color="blue">Debentures </font> and  <font color="blue">common stock</font> purchase warrants, we are <font color="blue">registering</font> an     <font color="blue">additional</font> 7dtta3 million shares of <font color="blue">common stock</font> issuable upon <font color="blue">conversion</font> or     <font color="blue">redemption</font> of, or <font color="blue">as interest payments on</font>, the <font color="blue">Debentures </font>and exercise of     the warrants</td>
    </tr>
    <tr>
      <td>The interest and principal are <font color="blue">payable monthly commencing</font>     July 1, and August 1, 2006, respectively, in shares of <font color="blue">common stock</font>, subject     to some <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td>In general, shares of registered <font color="blue">common stock</font> may be     re-sold into the <font color="blue"><font color="blue">public markets</font> without volume</font> or other <font color="blue">restrictions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Large     </font>sales of our <font color="blue">registered shares could</font> place substantial <font color="blue">downward pressure on</font>     the <font color="blue">trading price</font> of our <font color="blue">common stock</font>, particularly if the <font color="blue">amount sold</font>     <font color="blue">significant</font>ly exceeds the then-current trading volume of our stock</td>
    </tr>
    <tr>
      <td><font color="blue">Downward Pressure </font>on <font color="blue">Our Stock Price Could Result </font>if Certain Stockholders     Become Short-term Investors</td>
    </tr>
    <tr>
      <td>Provided we <font color="blue">meet certain requirements</font>, all     <font color="blue">outstanding principal</font> and <font color="blue">interest under</font> the <font color="blue">Debentures </font>may be paid in     shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Within 6 months after issuance, the warrants we     <font color="blue">concurrently sold become exercisable</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> the sale of these     securities, we agreed to <font color="blue">promptly register</font> the shares of our <font color="blue">common stock</font>     <font color="blue">issuable under</font> the Debentures, and upon exercise of the warrant, for re-sale     into the <font color="blue">public markets</font></td>
    </tr>
    <tr>
      <td>We may <font color="blue">enter into</font> similar financing <font color="blue">transaction</font>s in     the <font color="blue">future with</font> the same or <font color="blue">different investors</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">such investors</font>     typically receive <font color="blue">registered shares well</font> in advance of the expiration of the     holding periods under Rule 144 of the Securities Act, they may choose to     sell their shares after a short period of holding our stock</td>
    </tr>
    <tr>
      <td>If sufficient     quantities of stock are sold during a brief interval of time, this could     result in <font color="blue">downward pressure on</font> the <font color="blue">market price</font> for shares of our publicly     traded <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Four of our principal <font color="blue">stockholders</font>, David Platt, James Czirr,     Offer Binder and <font color="blue">Anatole Klyosov </font>own or control <font color="blue">approximately</font> 42prca of the     <font color="blue">outstanding shares</font> of our <font color="blue">common stock</font>, and Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Platt and Mr</font></td>
    </tr>
    <tr>
      <td>Some or all of these <font color="blue">stockholders</font>, acting in concert,     may  be  able  to <font color="blue">substantially</font> influence the election <font color="blue">of the Board </font>of     <font color="blue">Directors </font>and other <font color="blue">corporate actions</font> requiring stockholder approval, such     <font color="blue">as recapitalization</font> or other fundamental corporate action, as well as the     direction and policies of our company</td>
    </tr>
    <tr>
      <td>Such <font color="blue">concentration</font> of <font color="blue">ownership also</font>     could have the effect of delaying, deterring or preventing a change in     control of the company that <font color="blue">might otherwise</font> be <font color="blue">beneficial</font> to <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 and     related  <font color="blue">regulations</font>  may result in changes in <font color="blue">accounting</font> standards or     accepted practices within our industry and could add <font color="blue">significant</font> new costs     to being a public company</td>
    </tr>
    <tr>
      <td>New laws, <font color="blue">regulations</font> and <font color="blue">accounting</font> standards,     as well as changes to currently accepted <font color="blue">accounting</font> practices, including the     expensing of stock options, could adversely affect our reported financial     results and <font color="blue">negatively affect</font> our stock price</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">unanticipated</font>     <font color="blue">expenses incurred</font> to <font color="blue">comply with new requirements could also negatively</font>     impact our results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>